Samsung Sets New Standard for Flagship Mobile Processors with Exynos 2100
12.1.2021 18:05:00 EET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced the Exynos 2100 through its first virtual event, Exynos On 2021 (www.youtube.com/samsung). The new mobile processor is the company’s first premium 5G-integrated mobile processor built on the most advanced 5-nanometer (nm) extreme ultra-violet (EUV) process node.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005748/en/
Exynos 2100 introduced by Dr. Inyup Kang (Photo: Business Wire)
“Our Exynos team has been committed to creating premium mobile computing experiences by bringing innovations to processors that are at the heart of today’s smart devices,” said Inyup Kang, president of System LSI Business at Samsung Electronics. “Today we are delighted to introduce the Exynos 2100, our most advanced mobile processor yet. Armed with powerful processing technologies and an advanced 5G modem on a power-efficient 5nm process node, Exynos 2100 will set a new standard for tomorrow’s flagship mobile devices.”
“At Samsung Electronics, we are dedicated to providing innovative technologies and services with our flagship devices to deliver the ultimate mobile experience to our customers,” said Kyeongjun Kim, Executive Vice President and head of Mobile R&D Office at Mobile Communications Business, Samsung Electronics. “With powerful processing, fast 5G connectivity, and intelligent AI-acceleration, the Exynos 2100 offers the utmost performance that meets the stringent quality standards and requirements for our next generation smartphone.”
“The evolution of technologies such as 5G, advanced graphics and machine learning have been critical in enabling new mobile experiences,” said Paul Williamson, vice president and general manager, Client Line of Business at Arm. “Arm and Samsung have collaborated closely to incorporate Arm’s powerful next-generation compute and graphics platform, at the heart of the Samsung Exynos 2100. As a result of our partnership, we are able to maximize performance and make these experiences a reality in next-generation mobile devices while delivering exceptional battery life.”
The chip’s computation and graphic processing performance have been improved and refined to surpass the power user’s performance expectations. As Samsung’s first 5G-integrated flagship mobile processor, the Exynos 2100 is built on an advanced 5nm EUV process technology that allows up to 20-percent lower power consumption or 10-percent higher overall performance than the 7nm predecessor. For further enhancement, the chip offers improved cache memory utilization and a stronger scheduler. The octa-core CPU comes in an improved tri-cluster structure made up of a single powerful Arm® Cortex®-X1 core that runs at up to 2.9GHz, three high-performing Cortex-A78 cores and four power-efficient Cortex-A55 cores delivering more than 30-percent enhancement in multi-core performance than the predecessor.
The Arm Mali™-G78, which supports the latest APIs such as Vulkan and OpenCL, improves graphic performance by more than 40-percent for visually stunning and seamless graphics, enabling the most immersive on-screen mobile experiences yet, including gaming and AR/VR or MR(Mixed Reality). The Exynos 2100 also integrates advanced multi-IP governor (AMIGO) technology, which overlooks and optimizes power usages of CPU, GPU, and other processes, allowing longer use time even with intense on-screen activities. With such comprehensive efforts to increase energy efficiency of its products across software and hardware technologies, Samsung also continues its strive to help minimize the carbon footprint of tomorrow’s mobile devices.
AI capabilities will also enjoy a significant boost with the Exynos 2100. The newly-designed tri-core NPU has architectural enhancements such as minimizing unnecessary operations for high effective utilization and support for feature-map and weight compression. Exynos 2100 can perform up to 26-trillion-operations-per-second (TOPS) with more than twice the power efficiency than the previous generation. With on-device AI processing and support for advanced neural networks, users will be able to enjoy more interactive and smart features as well as enhanced computer vision performance in applications such as imaging.
The Exynos 2100’s advanced image signal processor (ISP) supports camera resolutions of up to 200-megapixels (Mp). It can connect up to six individual sensors and is able to process four concurrently for richer multi-camera experiences. With a multi-camera and frame processor (MCFP), the ISP can combine feeds from multiple cameras to improve zoom performance, enhance image quality for ultra-wide shots and more. With AI acceleration, the ISP offers a content-aware feature that quickly and seamlessly recognizes scenes, faces and objects and optimally adjusts the camera settings to capture the image with fuller detail.
The Exynos 2100’s integrated 5G modem supports 5G’s sub-6GHz and mmWave spectrums from 2G GSM/CDMA, 3G WCDMA and 4G LTE, for strong network coverage and reliability. The modem delivers a maximum downlink speed of up to 5.1-gigabits per second (Gbps) in sub-6-gigahertz (GHz) and 7.35Gbps in mmWave, or up to 3.0Gbps in 4G networks with 1024 Quadrature Amplitude Modulation (QAM) support.
The Exynos 2100 is currently in mass production.
For more information about Samsung’s Exynos products, please visit http://www.samsung.com/exynos.
|
Process |
5nm |
AI |
26 TOPS |
|
Multi-core |
Octa-core |
CPU (Main) |
Arm Cortex-X1 (2.9GHz) |
|
CPU (Sub) |
Arm Cortex-A78 and Cortex-A55 |
GPU |
Arm Mali-G78 |
|
Connectivity |
5G (sub-6GHz/mmWave), 4G LTE (1024 QAM), 3G WCDMA, 2G GSM/CDMA |
Memory |
LPDDR5 (51.2GB/s) |
|
Storage |
UFS 3.1, UFS 2.1 |
Camera (Rear) |
200MP |
|
Video (Encoding) |
4K UHD 120fps |
Video (Decoding) |
8K 60fps |
# # #
* Editor's Note: Actual performance may vary depending on device and user environment.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005748/en/
Contact information
Ujeong Jahnke
Samsung Semiconductor Europe GmbH
Tel. +49(0)89-45578-1000
Email: sseg.comm@samsung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom